Article

Oculus device receives FDA premarket approval

The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus).

Lynwood, WA-The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus). The device will be launched at the annual meeting of the American Academy of Ophthalmology in Atlanta.

The instrument is designed to photograph the eye and obtain a Scheimpflug image of the cornea to evaluate its thickness. The implanted ophthalmic refractometer measures the refractive power of the eye.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.